of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lisinoprillisinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.lithiumalfuzosin and lithium both increase QTc interval. Use Caution/Monitor.lofexidinelofexidine and alfuzosin both increase QTc interval. Use Caution/Monitor.loperamidealfuzosin and loperamide both increase QTc interval. Use Caution/Monitor.lopinavirlopinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.lorlatiniblorlatinib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lornoxicamlornoxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.lumefantrinelumefantrine and alfuzosin both increase QTc interval. Use Caution/Monitor.lurasidonelurasidone increases effects of alfuzosin by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.maprotilinemaprotiline and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and maprotiline both increase QTc interval. Use Caution/Monitor.maravirocmaraviroc, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.meclofenamatemeclofenamate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mefenamic acidmefenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mefloquinemefloquine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and mefloquine both increase QTc interval. Use Caution/Monitor.meloxicammeloxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.methadonemethadone and alfuzosin both increase QTc interval. Use Caution/Monitor.metoprololalfuzosin and metoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.mirtazapinealfuzosin and mirtazapine both increase QTc interval. Use Caution/Monitor.mitotanemitotane decreases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.moexiprilmoexipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.moxifloxacinmoxifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.moxisylytealfuzosin and moxisylyte both increase anti-hypertensive channel blocking. Use Caution/Monitor.nabumetonenabumetone decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nadololalfuzosin and nadolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.naproxennaproxen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nebivololalfuzosin and nebivolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.nevirapinenevirapine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nicardipinealfuzosin and nicardipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nifedipinealfuzosin and nifedipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nilotinibnilotinib and alfuzosin both increase QTc interval. Use Caution/Monitor.nisoldipinealfuzosin and nisoldipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nitroglycerin rectalnitroglycerin rectal, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .nortriptylinenortriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and nortriptyline both increase QTc interval. Use Caution/Monitor.octreotideoctreotide and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and octreotide both increase QTc interval. Use Caution/Monitor.ofloxacinofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and ofloxacin both increase QTc interval. Use Caution/Monitor.olanzapineolanzapine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesolodaterol inhaledalfuzosin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasondansetronondansetron and alfuzosin both increase QTc interval. Use Caution/Monitor.osilodrostatosilodrostat and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and osilodrostat both increase QTc interval. Use Caution/Monitor. Dose dependent QT prolongation - avoid drugs known to prolong the QT intervalosimertinibosimertinib and alfuzosin both increase QTc interval. Use Caution/Monitor.oxaliplatinoxaliplatin will increase the level or effect of alfuzosin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.oxaprozinoxaprozin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.oxymetazoline topicaloxymetazoline topical increases and alfuzosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.ozanimodozanimod and alfuzosin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.paliperidonepaliperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.panobinostatpanobinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.parecoxibparecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.paroxetineparoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.pasireotidealfuzosin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.pasireotide and alfuzosin both increase QTc interval. Use Caution/Monitor.pazopanibpazopanib and alfuzosin both increase QTc interval. Use Caution/Monitor.penbutololalfuzosin and penbutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.pentamidinepentamidine and alfuzosin both increase QTc interval. Use Caution/Monitor.perindoprilperindopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.perphenazineperphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and perphenazine both increase QTc interval. Use Caution/Monitor.phenoxybenzaminealfuzosin and phenoxybenzamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.phentolaminealfuzosin and phentolamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.pimavanserinpimavanserin and alfuzosin both increase QTc interval. Use Caution/Monitor.pimozidepimozide and alfuzosin both increase QTc interval. Use Caution/Monitor.pindololalfuzosin and pindolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.piroxicampiroxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.pitolisantpitolisant and alfuzosin both increase QTc interval. Use Caution/Monitor.posaconazoleposaconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.prazosinalfuzosin and prazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.primaquinealfuzosin and primaquine both increase QTc interval. Use Caution/Monitor.procainamideprocainamide and alfuzosin both increase QTc interval. Use Caution/Monitor.propafenonepropafenone and alfuzosin both increase QTc interval. Use Caution/Monitor.propranololalfuzosin and propranolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.protriptylineprotriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and protriptyline both increase QTc interval. Use Caution/Monitor.pseudoephedrinepseudoephedrine decreases effects of alfuzosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.quetiapinequetiapine and alfuzosin both increase QTc interval. Use Caution/Monitor.quinaprilquinapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.quinidinequinidine and alfuzosin both increase QTc interval. Use Caution/Monitor.ramiprilramipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.ranolazineranolazine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and ranolazine both increase QTc interval. Use Caution/Monitor.ribociclibribociclib and alfuzosin both increase QTc interval. Use Caution/Monitor.ribociclib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifabutinrifabutin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifampinrifampin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rilpivirinerilpivirine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and rilpivirine both increase QTc interval. Use Caution/Monitor.risperidonerisperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and risperidone both increase QTc interval. Use Caution/Monitor.romidepsinromidepsin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and romidepsin both increase QTc interval. Use Caution/Monitor.rucaparibrucaparib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.salicylates (non-asa)salicylates (non-asa) decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.salmeterolalfuzosin and salmeterol both increase QTc interval. Use Caution/Monitor.salsalatesalsalate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.saquinavirsaquinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.selpercatinibselpercatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.sertralinesertraline and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and sertraline both increase QTc interval. Use Caution/Monitor.silodosinalfuzosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.solifenacinsolifenacin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and solifenacin both increase QTc interval. Use Caution/Monitor.sorafenibsorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.sotalolalfuzosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.sotalol and alfuzosin both increase QTc interval. Use Caution/Monitor.St John's WortSt John's Wort will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.stiripentolstiripentol, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.sulfasalazinesulfasalazine decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sulindacsulindac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sunitinibsunitinib and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and sunitinib both increase QTc interval. Use Caution/Monitor.tacrolimustacrolimus and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and tacrolimus both increase QTc interval. Use Caution/Monitor.tadalafiltadalafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.tazemetostattazemetostat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.tecovirimattecovirimat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.telavancintelavancin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and telavancin both increase QTc interval. Use Caution/Monitor.terazosinalfuzosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.tetrabenazinetetrabenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.thioridazinethioridazine and alfuzosin both increase QTc interval. Use Caution/Monitor.timololalfuzosin and timolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.tolfenamic acidtolfenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tolmetintolmetin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.toremifenetoremifene and alfuzosin both increase QTc interval. Use Caution/Monitor.trandolapriltrandolapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.triclabendazolealfuzosin and triclabendazole both increase QTc interval. Use Caution/Monitor.trimipraminetrimipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and trimipramine both increase QTc interval. Use Caution/Monitor.triptorelintriptorelin and alfuzosin both increase QTc interval. Use Caution/Monitor.valbenazinevalbenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.vandetanibvandetanib and alfuzosin both increase QTc interval. Use Caution/Monitor.vardenafilvardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and vardenafil both increase QTc interval. Use Caution/Monitor.vemurafenibvemurafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.verapamilalfuzosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor.voclosporinvoclosporin, alfuzosin. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazolevoriconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.vorinostatvorinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and vorinostat both increase QTc interval. Use Caution/Monitor.ziprasidoneziprasidone and alfuzosin both increase QTc interval. Use Caution/Monitor.zotepinealfuzosin and zotepine both increase anti-hypertensive channel blocking. Use Caution/Monitor.Minor (59)acetazolamideacetazolamide will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.amobarbitalamobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.anastrozoleanastrozole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.aprepitantaprepitant will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.armodafinilarmodafinil will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.bosentanbosentan will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.brimonidinebrimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.budesonidebudesonide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.butabarbitalbutabarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.butalbitalbutalbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.butcher's broomalfuzosin, butcher's broom. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.chloroquinechloroquine and alfuzosin both increase QTc interval. Minor/Significance Unknown.conivaptanconivaptan will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cortisonecortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyclophosphamidecyclophosphamide will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyclosporinecyclosporine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.darifenacindarifenacin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dasatinibdasatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dexamethasonedexamethasone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.DHEA, herbalDHEA, herbal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dronedaronedronedarone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.eslicarbazepine acetateeslicarbazepine acetate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ethanolalfuzosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts.fluconazolefluconazole